{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:57:46Z","timestamp":1784746666567,"version":"3.55.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Rituximab plus bendamustine (R-B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice, many centers still prefer R-CHOP to R-B in patients with FL grade 3A (FL3A). Therefore, we retrospectively assessed patients with FL3A treated with either R-CHOP or R-B in five European cancer centers and compared their outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We retrospectively assessed 132 patients affected by FL grade 3A treated with either R-B or R-CHOP in the first line and evaluated outcome and toxicity according to the type of treatment. This study included 101 patients who were a subgroup of a previously published cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>R-B was less toxic and achieved a similar percentage of complete remissions compared with R-CHOP (97% vs. 96%, p\u2009=\u2009.3). During follow-up, 10 (16%) patients relapsed after R-B and 29 (41%) after R-CHOP (p\u2009=\u2009.001), leading to a median progression-free survival (PFS) of 15 versus 11.7 years, respectively (p\u2009=\u2009.03). Furthermore, R-B overcame the negative prognostic impact of BCL2 expression (15 vs. 4.8 years; p\u2009=\u2009.001). However, median overall survival was similar between both groups (not reached for both; p\u2009=\u2009.8).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>R-B as a first-line treatment of FL3A is better tolerated than R-CHOP and seems to induce more profound responses, leading to a significantly lower relapse rate and prolonged PFS. Therefore, R-B is a valid treatment option for FL grade 3A.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Rituximab plus bendamustine (R-B) has shown to be less toxic and more effective than rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma grade 3A. Although both regimens can induce a complete remission in &amp;gt;95% of patients, relapses occur more frequently after R-CHOP than R-B, leading to a significantly longer progression-free survival in the latter. R-B is also able to overcome the impact of negative prognosticators, such as BCL2 expression. However, because of the indolent course of this disease and efficient salvage treatments, overall survival was similar in both treatment groups. Therefore, R-B is a valid treatment option in this patient setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0037","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T16:12:18Z","timestamp":1515514338000},"page":"454-460","source":"Crossref","is-referenced-by-count":33,"title":["Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study"],"prefix":"10.1093","volume":"23","author":[{"given":"Patrizia","family":"Mondello","sequence":"first","affiliation":[{"name":"Department of Human Pathology, University of Messina, Messina, Italy"},{"name":"Department of Biological and Environmental Sciences, University of Messina, Messina, Italy"},{"name":"Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, Cornell University, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normann","family":"Steiner","sequence":"additional","affiliation":[{"name":"Internal Medicine V: Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[{"name":"Internal Medicine V: Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[{"name":"Haematology Division, \u201cFederico II\u201d University Hospital, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Nappi","sequence":"additional","affiliation":[{"name":"Haematology Division, \u201cFederico II\u201d University Hospital, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endri","family":"Mauro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pordenone General Hospital, Pordenone, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Department of Molecular Biotechnologies and Health Sciences, Division of Hematology AOU \u201cCitt\u00e0 della Salute e della Scienza di Torino,\u201d, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cuzzocrea","sequence":"additional","affiliation":[{"name":"Department of Biological and Environmental Sciences, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mian","sequence":"additional","affiliation":[{"name":"Haematology Division, \u201cFederico II\u201d University Hospital, Naples, Italy"},{"name":"Department of Hematology & CBMT, Ospedale di Bolzano, Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,9]]},"reference":[{"key":"2021122510435025500_onco12352-bib-0001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2559.2000.00895.x","article-title":"The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997","volume":"36","author":"Harris","year":"2000","journal-title":"Histopathology"},{"key":"2021122510435025500_onco12352-bib-0002","first-page":"213","article-title":"Follicular lymphoma: Expanding therapeutic options","volume":"19","author":"Ganti","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"2021122510435025500_onco12352-bib-0003","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2900010209","article-title":"Criteria for the cytologic subclassification of follicular lymphomas: A proposed alternative method","volume":"1","author":"Mann","journal-title":"Hematol Oncol;"},{"key":"2021122510435025500_onco12352-bib-0004","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0005","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0006","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0007","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9440(10)63313-5","article-title":"Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component","volume":"165","author":"Katzenberger","year":"2004","journal-title":"Am J Pathol"},{"key":"2021122510435025500_onco12352-bib-0008","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V101.3.1149","article-title":"Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive","volume":"101","author":"Bosga-Bouwer","year":"2003","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0009","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood.V93.7.2202","article-title":"Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features","volume":"93","author":"Rodriguez","year":"1999","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0010","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1008330311886","article-title":"Follicular large cell lymphoma: Long-term follow-up of 62 patients treated between 1973\u20131981","volume":"11","author":"Rodriguez","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122510435025500_onco12352-bib-0011","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1200\/JCO.1993.11.2.218","article-title":"Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0012","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0013","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.1994.12.7.1349","article-title":"Follicular large-cell lymphoma: Intermediate or low grade?","volume":"12","author":"Bartlett","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0014","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1200\/JCO.1997.15.4.1654","article-title":"Follicular large-cell lymphoma treated with intensive chemotherapy: An analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Wendum","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0015","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdl039","article-title":"Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska Lymphoma Study Group Experience","volume":"17","author":"Ganti","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122510435025500_onco12352-bib-0016","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0889-8588(05)70468-8","article-title":"Follicular lymphomas: Do histologic subtypes predict outcome?","volume":"11","author":"Miller","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122510435025500_onco12352-bib-0017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.bjc.6601006","article-title":"Outcome of follicular lymphoma grade 3: Is anthracycline necessary as front-line therapy?","volume":"89","author":"Chau","year":"2003","journal-title":"Br J Cancer"},{"key":"2021122510435025500_onco12352-bib-0018","doi-asserted-by":"crossref","first-page":"863","DOI":"10.5858\/2004-128-863-ACEOFL","article-title":"A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences","volume":"128","author":"Hsi","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"2021122510435025500_onco12352-bib-0019","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0020","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0021","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group hematology and oncology study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0022","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0023","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"2021122510435025500_onco12352-bib-0024","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00277-016-2668-0","article-title":"Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: Evidence from a multicenter, retrospective study","volume":"95","author":"Mondello","year":"2016","journal-title":"Ann Hematol"},{"key":"2021122510435025500_onco12352-bib-0026","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0027","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0028","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12308-009-0044-x","article-title":"A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: High clinical impact of a cumulative immunohistochemical outcome predictor score","volume":"2","author":"H\u00f6ller","year":"2009","journal-title":"J Hematop"},{"key":"2021122510435025500_onco12352-bib-0029","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0031","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0032","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/ctg.2013.13","article-title":"A primer on effectiveness and efficacy trials","volume":"5","author":"Singal","year":"2014","journal-title":"Clin Transl Gastroenterol"},{"key":"2021122510435025500_onco12352-bib-0033","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0034","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.12880","article-title":"Lymphoma diagnosis at an academic centre: Rate of revision and impact on patient care","volume":"166","author":"Bowen","year":"2014","journal-title":"Br J Haematol"},{"key":"2021122510435025500_onco12352-bib-0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2141.2003.04629.x","article-title":"The clinical impact of expert pathological review on lymphoma management: A regional experience","volume":"123","author":"Lester","year":"2003","journal-title":"Br J Haematol"},{"key":"2021122510435025500_onco12352-bib-0036","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2010.31.2223","article-title":"Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network","volume":"29","author":"Proctor","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0037","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.2008.16.4061","article-title":"Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network","volume":"26","author":"LaCasce","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0038","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0039","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.2011.34.7906","article-title":"Pathology review of outside material: When does it help and when can it hurt?","volume":"29","author":"Smith","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1385\/MO:18:1:15","article-title":"Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma","volume":"18","author":"Llanos","year":"2001","journal-title":"Med Oncol"},{"key":"2021122510435025500_onco12352-bib-0041","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.1994.12.1.149","article-title":"Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases","volume":"12","author":"Tang","year":"1994","journal-title":"J Clin Oncol"},{"key":"2021122510435025500_onco12352-bib-0042","first-page":"39","article-title":"Non-Hodgkin's lymphomas: Immunologic prognostic studies","volume":"28","author":"Hadzi-Pecova","year":"2007","journal-title":"Prilozi"},{"key":"2021122510435025500_onco12352-bib-0043","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/bjc.1994.61","article-title":"p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time","volume":"69","author":"Piris","year":"1994","journal-title":"Br J Cancer"},{"key":"2021122510435025500_onco12352-bib-0044","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/S1516-31802010000100004","article-title":"Bcl-2 protein frequency in patients with high-risk diffuse large B-cell lymphoma","volume":"128","author":"Hallack Neto","year":"2010","journal-title":"Sao Paulo Med J"},{"key":"2021122510435025500_onco12352-bib-0045","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.4081\/hr.2011.e26","article-title":"Significance of Bcl-2 and Bcl-6 immunostaining in B-non Hodgkin's lymphoma","volume":"3","author":"Mahmoud","year":"2011","journal-title":"Hematol Rep"},{"key":"2021122510435025500_onco12352-bib-0046","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2141.2002.03435.x","article-title":"Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma","volume":"117","author":"Barrans","year":"2002","journal-title":"Br J Haematol"},{"key":"2021122510435025500_onco12352-bib-0047","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.1073\/pnas.180316097","article-title":"Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas","volume":"97","author":"Lossos","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122510435025500_onco12352-bib-0048","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/modpathol.3800396","article-title":"Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis","volume":"18","author":"Berglund","year":"2005","journal-title":"Mod Pathol"},{"key":"2021122510435025500_onco12352-bib-0049","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2559.2003.01758.x","article-title":"Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance","volume":"43","author":"Leval","year":"2003","journal-title":"Histopathology"},{"key":"2021122510435025500_onco12352-bib-0050","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/00000478-200006000-00010","article-title":"CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas","volume":"24","author":"Dogan","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"2021122510435025500_onco12352-bib-0051","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2002-04-1286","article-title":"Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma","volume":"101","author":"Colomo","year":"2003","journal-title":"Blood"},{"key":"2021122510435025500_onco12352-bib-0052","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122510435025500_onco12352-bib-0053","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0037","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0037","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/4\/454\/41915444\/oncolo_23_4_454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/4\/454\/41915444\/oncolo_23_4_454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:45:06Z","timestamp":1640429106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/4\/454\/6439539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,9]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,1,9]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0037","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,1]]},"published":{"date-parts":[[2018,1,9]]}}}